In 60 older adults, 250 mg of oral NMN daily for 12 weeks increased blood NAD+-related measures. The NMN group walked four meters faster and reported better sleep scores, but the study’s primary stepping-test outcome did not differ from placebo. A separate trial in healthy older men used 250 mg daily for 12 weeks and reported nominal improvements in gait speed and left-hand grip strength. Muscle mass and body composition did not improve.

The broader picture is less impressive than these individual findings. A systematic review of 10 randomized NMN trials, involving 437 people and generally lasting four to 12 weeks, found that physical-performance measures were not significantly improved overall. In older adults

NAD+ has a plausible role in energy metabolism, but oral supplementation has not been shown to reliably increase everyday energy or reduce fatigue in adults. Exercise results vary by population, training program, precursor, and outcome. Some small studies suggest changes in exercise capacity or walking performance, while pooled evidence does not show a dependable improvement in physical function.

Claims about diabetes, cardiovascular disease, neurodegeneration, cognition, longevity, and healthspan go beyond current human proof. A trial registry documents research testing NR combined with exercise in people with Friedreich’s ataxia, but registration is not the same as a demonstrated result. Likewise,

The evidence for intravenous NAD+ itself is much thinner than the evidence for oral precursors. A recent systematic review found no eligible outcomes trials evaluating IV or intramuscular NAD+ for anti-aging or wellness indications. It identified only contextual pharmacokinetic information and limited nonrandomized evidence involving intravenous NMN. Therefore, claims that IV administration improves energy, cognition, recovery, or aging are not supported by established clinical outcomes.

Administration by infusion also creates risks that ingestion does not. The FDA has warned that food-grade NAD+ ingredients are not suitable for sterile compounding because microbial contamination and endotoxins can harm patients. Reported reactions after injectable NAD+ products included severe chills,

Short randomized trials generally found oral NR and NMN well tolerated. A 2026 meta-analysis of 15 NMN-related trials found no clear increase in overall or serious adverse events and no significant rise in two common liver-enzyme measures. NMN doses ranged from 250 to 2000 mg daily, and treatment lasted from two weeks to 24 weeks. That evidence supports short-term tolerability in the studied adults, not lifelong safety.

Niacin is different from NR and NMN. It is an established vitamin B3 compound with pharmacologic effects at higher doses, including flushing and possible effects on blood sugar and liver enzymes. Nicotinamide also has its own metabolism and safety considerations. People who

In 60 older adults, 250 mg of oral NMN daily for 12 weeks increased blood NAD+-related measures. The NMN group walked four meters faster and reported better sleep scores, but the study’s primary stepping-test outcome did not differ from placebo. A separate trial in healthy older men used 250 mg daily for 12 weeks and reported nominal improvements in gait speed and left-hand grip strength. Muscle mass and body composition did not improve.

The broader picture is less impressive than these individual findings. A systematic review of 10 randomized NMN trials, involving 437 people and generally lasting four to 12 weeks, found that physical-performance measures were not significantly improved overall. In older adults

NAD+ has a plausible role in energy metabolism, but oral supplementation has not been shown to reliably increase everyday energy or reduce fatigue in adults. Exercise results vary by population, training program, precursor, and outcome. Some small studies suggest changes in exercise capacity or walking performance, while pooled evidence does not show a dependable improvement in physical function.

Claims about diabetes, cardiovascular disease, neurodegeneration, cognition, longevity, and healthspan go beyond current human proof. A trial registry documents research testing NR combined with exercise in people with Friedreich’s ataxia, but registration is not the same as a demonstrated result. Likewise,

The evidence for intravenous NAD+ itself is much thinner than the evidence for oral precursors. A recent systematic review found no eligible outcomes trials evaluating IV or intramuscular NAD+ for anti-aging or wellness indications. It identified only contextual pharmacokinetic information and limited nonrandomized evidence involving intravenous NMN. Therefore, claims that IV administration improves energy, cognition, recovery, or aging are not supported by established clinical outcomes.

Administration by infusion also creates risks that ingestion does not. The FDA has warned that food-grade NAD+ ingredients are not suitable for sterile compounding because microbial contamination and endotoxins can harm patients. Reported reactions after injectable NAD+ products included severe chills,

Short randomized trials generally found oral NR and NMN well tolerated. A 2026 meta-analysis of 15 NMN-related trials found no clear increase in overall or serious adverse events and no significant rise in two common liver-enzyme measures. NMN doses ranged from 250 to 2000 mg daily, and treatment lasted from two weeks to 24 weeks. That evidence supports short-term tolerability in the studied adults, not lifelong safety.

Niacin is different from NR and NMN. It is an established vitamin B3 compound with pharmacologic effects at higher doses, including flushing and possible effects on blood sugar and liver enzymes. Nicotinamide also has its own metabolism and safety considerations. People who